文献速递精神分裂症与精神病性障碍

基线抗精神病药剂量与临床高风险个体转化为精神病的剂量效应分析

Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该系统综述与荟萃分析纳入8项研究、290例基线暴露于抗精神病药的临床高风险个体,比较转化为精神病者与未转化者的基线平均氯丙嗪等效剂量。

要点

  • 临床高风险个体基线抗精神病药剂量越高,转化为精神病的可能性越大。
  • 转化者与未转化者基线平均氯丙嗪等效剂量范围分别为60-395 mg/d和13-224 mg/d。
  • 该剂量效应关联可改善基于CHR-P标准的起病时风险分层。

核心结论

  • 在基线暴露于抗精神病药的临床高风险个体中,接受较高抗精神病药剂量的个体转化为精神病的可能性增加。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Cochrane Library至2023年8月31日,纳入8项报告基线抗精神病药暴露及按转化状态分组剂量信息的研究。
  • 共纳入290例基线暴露于抗精神病药的临床高风险个体(平均[SD]年龄19.4[2.6]岁),其中66例转化为精神病,224例未转化。

主要发现

  • 转化者基线平均氯丙嗪等效剂量范围为60-395 mg/d,未转化者为13-224 mg/d。

临床怎么用

  • 对基线接受抗精神病药治疗的临床高风险个体,应记录具体剂量(如氯丙嗪等效剂量)以辅助预后风险分层。

局限性

  • 纳入研究均为非随机设计,证据质量受原始研究限制。
  • 样本量较小(共290例),可能影响结果的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Emerging meta-analytical evidence indicates that baseline exposure to antipsychotics is associated with an increased risk of transitioning to psychosis in individuals at clinical high-risk for psychosis (CHR-P) and that such effect is not a result of pretest risk enrichment. However, to maximize its translational utility for prognostic stratification in clinical practice, testing for the potential presence of a dose-response association is crucial. OBJECTIVE: To test whether the negative prognostic effect of baseline antipsychotic exposure in individuals at CHR-P follows a dose-effect pattern, as indicated by mean chlorpromazine equivalent doses (CPZ-ED). DATA SOURCES: MEDLINE and Cochrane Library, performed up to August 31, 2023, searching for English-language studies on individuals at CHR-P reporting data on exposure to antipsychotics at baseline and detailed information on dosage by transition status. STUDY SELECTION: Studies that provided information on antipsychotic exposure at baseline and included detailed dosage data categorized by transition status. DATA EXTRACTION AND SYNTHESIS: Eligible studies were identified following PRISMA guidelines and evaluated independently by 2 reviewers with the Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses. MAIN OUTCOMES AND MEASURES: The primary outcome was transition to psychosis in individuals at CHR-P who were receiving antipsychotic treatment at baseline, measured by baseline mean CPZ-ED in individuals at CHR-P who transitioned to psychosis compared to those who did not. RESULTS: Eight studies were included in the systematic review and meta-analysis. Among 290 individuals at CHR-P (mean [SD] age, 19.4 [2.6] years) who were exposed to antipsychotics at baseline and remained in contact up to the completion of the study, 66 converted to psychosis and 224 did not. The mean CPZ-ED ranged 60 to 395 mg/d in those who converted and 13 to 224 mg/d in those who did not. Those who converted to psychosis had higher CPZ-ED than those who did not in both the common-effects model (Hedges g, 0.41; 95% CI, 0.12-0.70; z, 2.78; P = .005) and in the random-effects model (Hedges g, 0.41; 95% CI, 0.15-0.67; z, 3.69; P = .008; τ2, 0.0). There was no relevant heterogeneity (Cochran Q, 3.99; df, 7; P = .78; I2, 0.0%; 95% CI, 0.0-68.0). The radial plot indicated a good fit of the model. CONCLUSIONS AND RELEVANCE: In individuals at CHR-P who were exposed to antipsychotics at baseline, those receiving higher antipsychotic doses demonstrated an increased likelihood of transitioning to psychosis. This meta-analytic evidence of putative dose-effect association confirms that baseline antipsychotic exposure and the corresponding dosage carry salient prognostic information that could improve current CHR-P criteria-based risk stratification at inception.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Raballo A, Poletti M, Preti A, et al. Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024. PMID: 38506802. doi:10.1001/jamapsychiatry.2024.0178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。